| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Lexaria Bioscience Corp. | Chief Executive Officer, Director | Stock Options | 350,000 | $304,500 | $0.8700 | 29 Jul 2025 | Direct |
| Lexaria Bioscience Corp. | Chief Executive Officer, Director | common shares | 65,000 | $59,111 | $0.9094 | 29 Jul 2025 | Direct |
| INVIVO THERAPEUTICS HOLDINGS CORP. | Chief Financial Officer | Stock Option (right to buy) | 20,800 | 17 Nov 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| LEXX | Lexaria Bioscience Corp. | 29 Jul 2025 | 1 | +$13,641 | 4 | Chief Executive Officer, Director | 30 Jul 2025, 11:14 |
| LEXX | Lexaria Bioscience Corp. | 15 May 2025 | 1 | $0 | 4 | Chief Executive Officer, Director | 16 May 2025, 17:47 |
| LEXX | Lexaria Bioscience Corp. | 02 Dec 2024 | 2 | +$118,392 | 4 | Chief Executive Officer | 03 Dec 2024, 14:03 |
| LEXX | Lexaria Bioscience Corp. | 31 Aug 2024 | 0 | $0 | 3 | Chief Executive Officer | 05 Sep 2024, 13:09 |
| /report/000110465922120834-christopher-richard-2022-11-17 | INVIVO THERAPEUTICS HOLDINGS CORP. | 17 Nov 2022 | 1 | $0 | 4 | Chief Financial Officer | 21 Nov 2022, 16:05 |